Home » Clinical Trials » Therapeutic Areas

Therapeutic Areas: Healthy Volunteers
Disease Category: Healthy Patient Studies
Location: United States, AZ

Clinical Trial Details

Overview

Research Study Summary

The Zogenix Dravet Syndrome Study

Purpose
To assess whether an investigational drug called ZX008 can reduce the number of seizures experienced by children and young adults who have Dravet Syndrome. Current effective treatment options for Dravet Syndrome are limited, making this research very important.
To Learn more

CW ID: 223042
Date Last Changed: February 8, 2017

Clinical Trial Snapshot

Phase
3
Gender
Both Male and Female
Age
2 to 18 Years
Overall Status
Recruiting
Lead Sponsor
Zogenix International Ltd.
Duration
26 Weeks
Facility Type
Out-Patient

Eligibility

Children or young adults who:
  • Have Dravet Syndrome.
  • Are between the ages of 2 and 18 years of age.
  • Have uncontrolled seizures despite current medications.
  • Have experienced their first seizure before their first birthday.

More Info

Once the main study is over, eligible participants may be able to take part in an optional open-label extension study. All participants in the extension study will take ZX008.

Contact

Margie Pazzi, RN, BSN, Research Nurse and Site Director
Center for Neurosciences
2450 E. River Road
Tucson, AZ 85712
Phone: 520-320-2147
Fax: 520-320-2149

View Map

Research Center Information:

Center for Neurosciences

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.